Shahla Rezaei

Shahla Rezaei

Auto-generated profile, based on publicly available information

Shahla Rezaei

Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 September 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
MAMaryam Akbari
Maryam Akbari
MVMohebat Vali
Mohebat Vali
SRShahla Rezaei
Shahla Rezaei
SBSina Bazmi
Sina Bazmi
RTReza Tabrizi
Reza Tabrizi
KLKamran Bagheri Lankarani
Kamran Bagheri Lankarani

9 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PNPeyman Nowrouzi-Sohrabi
Peyman Nowrouzi-Sohrabi
RTReza Tabrizi
Reza Tabrizi
MJMohammad Jalali
Mohammad Jalali
NJNavid Jamali
Navid Jamali
SRShahla Rezaei
Shahla Rezaei
SSSaeid Safiri
Saeid Safiri
Introduction: A systematic review and meta-analysis of clinical trials were undertaken to evaluate the effect of diacerein intake on cardiometabolic profiles in patients with type 2 diabetes mellitus (T2DM). Methods: Electronic databases such as PubMed, EMBASE, Scopus, Web of Science, Google Scholar, and Cochrane Central Register of Controlled Trials were searched from inception to 31 July 2019. Statistical heterogeneity was evaluated using Cochran’s Q test and I-square (I2) statistic. Data were pooled using random-effects models and weighted mean difference (WMD). Results: From 1,733 citations, seven clinical trials were eligible for inclusion and meta-analysis. A significant reduction in hemoglobin A1c (HbA1c) (WMD -0.73; 95%CI -1.25 to -0.21; P= 0.006; I2= 72.2%) and body mass index (BMI) (WMD -0.55; 95%CI -1.03 to -0.07; P= 0.026; I2= 9.5%) was identified. However, no significant effect of diacerein intake was identified on fasting blood sugar (FBS) (WMD -9.00; 95%CI -22.57 to 4.57; P= 0.194; I2= 60.5%), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD 0.39; 95%CI -0.95 to 1.73; P= 0.569; I2= 2.2%), body weight (WMD - 0.54; 95%CI -1.10 to 0.02; P= 0.059), triglycerides (WMD -0.56; 95%CI -24.16 to 23.03; P= 0.963; I2= 0.0%), total-cholesterol (WMD -0.21; 95%CI -12.19 to 11.78; P= 0.973; I2= 0.0%), HDL-cholesterol (WMD -0.96; 95%CI -2.85 to 0.93; P= 0.321; I2= 0.0%), and LDL-cholesterol levels (WMD -0.09; 95%CI -8.43 to 8.25; P= 0.983; I2= 37.8%). Conclusion: Diacerein intake may reduce HbA1c and BMI; however, no evidence of the effect was observed for FBS, HOMA-IR, body weight, triglycerides, total cholesterol, HDL-cholesterol or LDLcholesterol.

25 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RTReza Tabrizi
Reza Tabrizi
KLKamran Bagheri Lankarani
Kamran Bagheri Lankarani
PNPeyman Nowrouzi-Sohrabi
Peyman Nowrouzi-Sohrabi
MSMojtaba Shabani-Borujeni
Mojtaba Shabani-Borujeni
SRShahla Rezaei
Shahla Rezaei
MAMohammad Ali Ashraf
Mohammad Ali Ashraf
Background: COVID_19 is unpredictable due to non-specific symptoms and clinical course diversity in different individuals. We analyzed studies regarding the factors associated with severe status of the disease to identify unique findings in severely affected patients. Methods: We systematically searched the electronic databases, including PubMed, Scopus, EMBASE, Web of Science, and Google Scholar from inception to 12 th of March 2020. Cochrane’s Q and I-square statistics were used to assess the existence of heterogeneity between the included studies. We used the random-effects model to pool the odds ratios (ORs) at 95% confidence intervals (CIs). Results: Seventeen articles out of 3009 citations were included. These contained 3189 patients, of whom 732 were severely affected (severe group) and 3189 were in non-severe group. Using the random-effects model, our meta-analyses showed that the odds of comorbidities, including COPD, DM, HTN, CVD, CKD, and symptoms, including dyspnea, dizziness, anorexia, and cough, were significantly higher among the severe group compared with the non-severe group. There were no significant changes in odds of CVA, liver disease, immunodeficiency/immunosuppression, fever, fatigue, myalgia, headache, diarrhea, sore throat, nasal congestion, sputum, nausea, vomiting, chest pain between the two groups. Conclusions: Early recognition and intervention can be critical in management, and might stop progression to severe disease. Predictive symptoms and comorbidities can be used as a predictor in patients who are at risk of severe disease.